Cargando…

Safety, tolerability, and pharmacokinetics of an anti-LAG-3 antibody SHR-1802 in patients with advanced solid tumors: a phase I dose-escalation and dose-expansion study

BACKGROUND: Lymphocyte-activation gene 3 (LAG-3), a checkpoint molecule contributing to immune suppressive microenvironment, is regarded as a promising target in cancer treatment. SHR-1802 is a novel anti-LAG-3 monoclonal antibody. OBJECTIVES: To evaluate the safety, tolerability, pharmacokinetics,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deng, Ting, Liu, Zhigang, Han, Zhengquan, Zhou, Huan, Liu, Rui, Li, Yijing, Li, Shaorong, Xiu, Peng, Wang, Shuni, Zhang, Yiping, Ba, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387801/ https://www.ncbi.nlm.nih.gov/pubmed/37529157 http://dx.doi.org/10.1177/17588359231186025

Ejemplares similares

Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors
por: Li, Huiping, et al.
Publicado: (2020)

Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial
por: Liu, Dan, et al.
Publicado: (2022)

Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study
por: Mo, Hongnan, et al.
Publicado: (2018)

A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer
por: Chen, Justin A., et al.
Publicado: (2022)

Pharmacokinetics of escalating single‐dose administration of cannabidiol to cats
por: Rozental, Aaron J., et al.
Publicado: (2022)

Multiple doses of SHR-1222, a sclerostin monoclonal antibody, in postmenopausal women with osteoporosis: A randomized, double-blind, placebo-controlled, dose-escalation phase 1 trial
por: Dai, Zhijie, et al.
Publicado: (2023)

Safety, Tolerability, and Pharmacokinetics of JNJ-1802, a Pan-serotype Dengue Direct Antiviral Small Molecule, in a Phase 1, Double-Blind, Randomized, Dose-Escalation Study in Healthy Volunteers
por: Ackaert, Oliver, et al.
Publicado: (2023)

First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors
por: Li, Tianhong, et al.
Publicado: (2016)

Single Dose of SHR-1222, a Sclerostin Monoclonal Antibody, in Healthy Men and Postmenopausal Women With Low Bone Mass: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase I Study
por: Dai, Zhijie, et al.
Publicado: (2021)

Pharmacokinetics of zonisamide after oral single dosing and multiple‐dose escalation administration in domestic chickens (Gallus gallus)
por: de Matos, Ricardo, et al.
Publicado: (2021)

A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies
por: Ho, Jingshan, et al.
Publicado: (2022)

Open‐Label, Dose‐Escalation, Phase 1 Study of Safety and Single and Multiple‐Dose Pharmacokinetics of Dichlorphenamide in Healthy Volunteers
por: Cohen, Fredric
Publicado: (2018)

Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study
por: Borgå, Olof, et al.
Publicado: (2019)

PB1971: A PHASE 1 MULTICENTER OPEN-LABEL DOSE-ESCALATION AND DOSE-EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, EFFICACY OF HS-10382 (TERN-70) IN CHRONIC MYELOID LEUKEMIA PATIENTS
por: LI, Weiming, et al.
Publicado: (2023)

Bonaparte, 1769-1802 /
por: Gueniffey, Patrice
Publicado: (2018)

Medical Lectures for 1802
Publicado: (1802)

Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial
por: Shi, Yuankai, et al.
Publicado: (2022)

Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies
por: Brada, M, et al.
Publicado: (1999)

Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034
por: Bissett, D, et al.
Publicado: (2001)

Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study
por: Sarantopoulos, John, et al.
Publicado: (2017)

Safety, tolerability, pharmacokinetics and pharmacodynamics of parenterally administered dutogliptin: A prospective dose‐escalating trial
por: Buchtele, Nina, et al.
Publicado: (2020)

Phase I dose-escalation, safety, and CNS pharmacokinetic study of dexanabinol in patients with brain cancer
por: Juarez, Tiffany M, et al.
Publicado: (2021)

Dose escalation of a curcuminoid formulation
por: Lao, Christopher D, et al.
Publicado: (2006)

Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis
por: Song, Yue, et al.
Publicado: (2023)

Evaluation of the Effect of Food on the Pharmacokinetics of SHR6390, An Oral CDK4/6 Inhibitor, in Healthy Volunteers
por: Liu, Yan-ping, et al.
Publicado: (2022)

Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours
por: Lickliter, Jason D., et al.
Publicado: (2021)

Donald Monro (1727–1802)
Publicado: (1971)

On the Epidemic Distempers of the Year 1802
por: Potter, Nathaniel
Publicado: (1804)

Medical Society, London, 1802
Publicado: (1802)

A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
por: Harding, James J., et al.
Publicado: (2021)

A Phase I Dose Escalation and Expansion Study of Epidiolex (Cannabidiol) in Patients with Biochemically Recurrent Prostate Cancer
por: Myint, Zin W., et al.
Publicado: (2023)

Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study
por: Zhang, Wen, et al.
Publicado: (2022)

Phase 1 First-in-Human Dose Escalation and Dose Expansion Study of KLS-1 (64Zinc Aspartate) in Patients With Cancer and Neurodegenerative Diseases
por: Perez, Jesus A, et al.
Publicado: (2022)

Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta® in Healthy Chinese Male Volunteers
por: Cui, Yingzi, et al.
Publicado: (2021)

A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
por: Padda, Sukhmani K., et al.
Publicado: (2011)

Pharmacogenomic–pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer
por: Ishiguro, Hiroshi, et al.
Publicado: (2019)

Phase 1 Dose‐Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers
por: Miyoshi, So, et al.
Publicado: (2019)

Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
por: Sands, Bruce E., et al.
Publicado: (2019)

Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours
por: Lickliter, Jason D., et al.
Publicado: (2021)

An open‐label, dose‐escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension
por: Simon, Marc A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pfpdb26v2ol6i3dtlq7a2lcma1